Skip to content

Head to head

BPC-157 against Lorecivivint

The knee people are actually asking about. One of these went through two phase 3 trials and missed its pain endpoint in both; the other has never been tested in a knee trial in humans and is injected on the basis of rat tendon and ligament studies.

Column A

BPC-157

Body Protection Compound 157

A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.

Column B

Lorecivivint

Lorecivivint (SM04690)

An injected Wnt-pathway small molecule for knee osteoarthritis whose two published Phase 3 pain trials both missed their primary endpoint, now filed with the FDA in January 2026 on long-term joint-space-width data instead.

Side by side, on the facts we can check

AttributeBPC-157Lorecivivint
CategoryHealing & RecoveryHealing & Recovery
FDA statusNot FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA actionNDA under FDA review (submitted January 2026)
Half-lifeUnder 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days.One to two intra-articular injections per year
Molecular weight1,419.5 Da505.5 Da
MechanismIn animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days.Intra-articular CLK/DYRK1A inhibition that modulates Wnt signaling, reducing inflammation and promoting chondrocyte health.
Human studies cited53
Legal status, USNot approved; research use onlyInvestigational, not approved
open the BPC-157 profileopen the Lorecivivint profile

Frequently asked questions

What is the difference between BPC-157 and Lorecivivint?

BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Lorecivivint: An injected Wnt-pathway small molecule for knee osteoarthritis whose two published Phase 3 pain trials both missed their primary endpoint, now filed with the FDA in January 2026 on long-term joint-space-width data instead.

Which has stronger research evidence, BPC-157 or Lorecivivint?

This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 3 of 3 for Lorecivivint. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are BPC-157 and Lorecivivint FDA-approved?

BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Lorecivivint: NDA under FDA review (submitted January 2026).

Related posts

Blog articles that cover BPC-157 or Lorecivivint, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.